These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21953603)

  • 41. Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson's disease according to task demands.
    Sharma K; Fallon SJ; Davis T; Ankrett S; Munro G; Christopher G; Coulthard E
    Psychopharmacology (Berl); 2022 Feb; 239(2):605-619. PubMed ID: 35006304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
    Simon DK; Wu C; Tilley BC; Wills AM; Aminoff MJ; Bainbridge J; Hauser RA; Schneider JS; Sharma S; Singer C; Tanner CM; Truong D; Wong PS
    Clin Neuropharmacol; 2015; 38(5):163-9. PubMed ID: 26366971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis.
    Hong CT; Chan L; Bai CH
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32580456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Caffeine in Parkinson's disease: comment on its importance and the dose proposal.
    Kitagawa M; Houzen H; Tashiro K
    Mov Disord; 2012 May; 27(6):808. PubMed ID: 22499388
    [No Abstract]   [Full Text] [Related]  

  • 45. Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot study.
    Orlikov A; Ryzov I
    Biol Psychiatry; 1991 Feb; 29(4):391-6. PubMed ID: 2036480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating the Validity of Caffeine Use Disorder.
    Budney AJ; Lee DC; Juliano LM
    Curr Psychiatry Rep; 2015 Sep; 17(9):74. PubMed ID: 26220829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some methodological issues in the conduct of caffeine research.
    Grossman EM
    Food Chem Toxicol; 1984 Mar; 22(3):245-9. PubMed ID: 6368339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Caffeine in Pain Management: A Brief Literature Review.
    Baratloo A; Rouhipour A; Forouzanfar MM; Safari S; Amiri M; Negida A
    Anesth Pain Med; 2016 Jun; 6(3):e33193. PubMed ID: 27642573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comment: Caffeine and PD-Time to consider other interventions.
    Hall CB
    Neurology; 2017 Oct; 89(17):1802. PubMed ID: 28954875
    [No Abstract]   [Full Text] [Related]  

  • 50. Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough.
    Munoz DG; Fujioka S
    Neurology; 2018 Jan; 90(5):205-206. PubMed ID: 29298853
    [No Abstract]   [Full Text] [Related]  

  • 51. Caffeine for treatment of Parkinson disease: a randomized controlled trial.
    Postuma RB; Lang AE; Munhoz RP; Charland K; Pelletier A; Moscovich M; Filla L; Zanatta D; Rios Romenets S; Altman R; Chuang R; Shah B
    Neurology; 2012 Aug; 79(7):651-8. PubMed ID: 22855866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Caffeine and risk of Parkinson's disease in a large cohort of men and women.
    Palacios N; Gao X; McCullough ML; Schwarzschild MA; Shah R; Gapstur S; Ascherio A
    Mov Disord; 2012 Sep; 27(10):1276-82. PubMed ID: 22927157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
    Rivera-Oliver M; Díaz-Ríos M
    Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease.
    Qi H; Li S
    Geriatr Gerontol Int; 2014 Apr; 14(2):430-9. PubMed ID: 23879665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Caffeine in Parkinson disease: better for cruise control than snooze patrol?
    Schwarzschild MA
    Neurology; 2012 Aug; 79(7):616-8. PubMed ID: 22855870
    [No Abstract]   [Full Text] [Related]  

  • 56. Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.
    Sonsalla PK; Wong LY; Harris SL; Richardson JR; Khobahy I; Li W; Gadad BS; German DC
    Exp Neurol; 2012 Apr; 234(2):482-7. PubMed ID: 22309831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Caffeine consumption and the 4-year progression of de novo Parkinson's disease.
    Moccia M; Erro R; Picillo M; Vitale C; Longo K; Amboni M; Pellecchia MT; Barone P
    Parkinsonism Relat Disord; 2016 Nov; 32():116-119. PubMed ID: 27622969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism.
    Fernández-Dueñas V; Gómez-Soler M; López-Cano M; Taura JJ; Ledent C; Watanabe M; Jacobson KA; Vilardaga JP; Ciruela F
    ACS Chem Biol; 2014 Nov; 9(11):2496-501. PubMed ID: 25268872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer's Disease and Parkinson's Disease.
    Tapias V; González-Andrés P; Peña LF; Barbero A; Núñez L; Villalobos C
    Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37372013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.
    Zhao Y; Liu X; Yang G
    Mol Neurobiol; 2023 Jun; 60(6):3054-3070. PubMed ID: 36786912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.